AdFalciVax Vaccine

Recently, the Indian Council of Medical Research (ICMR) granted non-exclusive rights for its multi-stage malaria vaccine, AdFalciVax, to five pharmaceutical companies. This development marks a significant step in India's efforts to combat malaria, especially the Plasmodium falciparum parasite, which is responsible for the majority of malaria-related deaths globally.

About AdFalciVax Vaccine

AdFalciVax is India’s first indigenous multi-stage malaria recombinant vaccine. It was developed by the Regional Medical Research Centre (RMRC), Bhubaneswar, under the ICMR. The vaccine targets one of the deadliest forms of malaria, caused by the Plasmodium falciparum parasite, which has been particularly challenging to control.

Key Features of AdFalciVax

1. Targeting Plasmodium falciparum:

   • The vaccine is designed to prevent infection by the Plasmodium falciparum parasite and reduce community transmission.

   • Plasmodium falciparum is the deadliest form of the malaria parasite, responsible for severe complications and widespread devastation, particularly in tropical regions.

2. Dual-Antigen Approach:

   • AdFalciVax uses a dual-antigen approach, which combines multiple targets on the malaria parasite to improve efficacy:

     • PfCSP (Plasmodium falciparum circumsporozoite protein): Prevents infection by blocking the parasite's entry into the bloodstream.

     • Pfs230 and Pfs48/45 fusion proteins: These proteins are designed to block the transmission of malaria from humans to mosquitoes, thus reducing the spread of the disease within the community.

3. Innovative Technology:

   • The vaccine utilizes Lactococcus lactis, a genetically engineered food-grade bacterial host, as the core technology to produce the recombinant proteins for the vaccine.

4. Impact on Malaria Transmission:

   • By targeting the parasite before it enters the bloodstream, AdFalciVax aims not only to protect individuals but also to halt the transmission cycle of malaria, offering a broader community-level solution.

5. Pre-clinical Validation:

   • The pre-clinical validation of the vaccine was carried out in collaboration with the ICMR-National Institute of Malaria Research (ICMR-NIMR) and the National Institute of Immunology (NII), Delhi, under the Department of Biotechnology.

Significance of AdFalciVax

• First Indigenous Malaria Vaccine: This is a groundbreaking achievement, as AdFalciVax is India’s first indigenous vaccine developed specifically for malaria.

• Multi-Stage Protection: Unlike other malaria vaccines, AdFalciVax targets both the parasite and transmission stage, making it a multi-functional vaccine. This dual approach could be more effective in controlling and potentially eradicating malaria.

• Global Potential: Given malaria’s continued threat in tropical and subtropical regions, especially in Sub-Saharan Africa and South Asia, the vaccine has the potential to be a global game-changer in the fight against malaria.

Next Steps and Industry Collaboration

With the non-exclusive rights granted to five pharmaceutical companies, AdFalciVax will undergo further scaling, production, and distribution efforts. This collaboration between ICMR and the private sector aims to accelerate the availability of the vaccine for wider populations, especially in malaria-endemic regions.

Conclusion

The development of AdFalciVax represents a major breakthrough in malaria research and public health. Its multi-stage action not only protects individuals from infection but also plays a crucial role in reducing the spread of malaria in the community. With further collaboration between public and private sectors, AdFalciVax could become an essential tool in the fight to eradicate malaria worldwide